A phase II trial assessing immunogenicity and safety of COVID-19 mRNA Vaccine BNT162b2 in adult volunteers with no history of SARS-CoV-2 infection administered with two doses of vaccine (D1-D29) and in adult volunteers with documented history of SARS-CoV-2 infection (of more than 5 months)...